希玛医疗二零二五年中期报告

2025INTERIM REPORT中期報告 Contents 目錄 Corporate Information2公司資料Financial Highlights5財務概要Management Discussion and Analysis6管理層討論及分析Interim Condensed Consolidated Statement ofComprehensive Income26中期簡明綜合全面收益表Interim Condensed Consolidated Statement ofFinancial Position28中期簡明綜合財務狀況表Interim Condensed Consolidated Statement ofChanges in Equity30中期簡明綜合權益變動表Interim Condensed Consolidated Statement of Cash Flows32中期簡明綜合現金流量表Notes to the Interim Condensed Consolidated FinancialInformation34中期簡明綜合財務資料附註Report on Review of Interim Financial Information88中期財務資料的審閱報告Other Information90其他資料 Corporate Information公司資料 BOARD OF DIRECTORSExecutive Directors 董事會 Dr. LAM Shun Chiu Dennis(Chairman and Chief Executive Officer)(resigned with effect from 1 June 2025)Ms. LI Xiaoting (appointed as Vice Chairman andChief Executive Officer with effect from 1 June 2025)Dr. LEE Yau Wing Vincent 林順潮醫生（主席兼行政總裁）（自2025年6月1日起辭任）李肖婷女士（自2025年6月1日起獲委任為副主席兼行政總裁）李佑榮醫生 獨立非執行董事 Independent Non-executive Directors Dr. Rex AUYEUNG Pak-kuen(appointed as Chairman with effect from 1 June 2025)Dr. KO Wing Man(appointed as independent non-executive Director andVice Chairman with effect from 1 June 2025)Mr. MA Andrew Chiu CheungMr. IP Shu Kwan StephenMr. YIN KeMr. LI Ling Cheung Raymond(appointed with effect from 1 June 2025) 歐陽伯權博士（於2025年6月1日獲委任為主席）高永文醫生（自2025年6月1日起獲委任為獨立非執行董事兼副主席）馬照祥先生葉澍堃先生殷可先生李令翔先生（於2025年6月1日獲委任） 董事會委員會審核委員會馬照祥先生（主席）葉澍堃先生李令翔先生 BOARD COMMITTEESAudit Committee Mr. MA Andrew Chiu Cheung(Chairperson)Mr. IP Shu Kwan StephenMr. LI Ling Cheung Raymond 薪酬委員會 Remuneration Committee Mr. IP Shu Kwan Stephen(Chairperson)Mr. YIN KeMr. LI Ling Cheung Raymond 葉澍堃先生（主席）殷可先生李令翔先生 提名委員會 歐陽伯權博士（主席）李肖婷女士高永文醫生 Nomination Committee Dr. Rex AUYEUNG Pak-kuen(Chairperson)Ms. LI XiaotingDr. KO Wing Man 授權代表 AUTHORIZED REPRESENTATIVES 李肖婷女士陳華平先生 Ms. LI XiaotingMr. CHAN Wa Ping 公司秘書陳華平先生 COMPANY SECRETARYMr. CHAN Wa Ping 核數師 AUDITOR 羅兵咸永道會計師事務所執業會計師註冊公眾利益實體核數師香港中環太子大廈22樓 PricewaterhouseCoopersCertified Public AccountantsRegistered Public Interest Entity Auditor22/F, Prince’s BuildingCentralHong Kong 註冊辦事處 REGISTERED OFFICE Cricket Square, Hutchins DriveP.O. Box 2681 Grand CaymanKY1-1111Cayman Islands Cricket Square, Hutchins DriveP.O. Box 2681 Grand CaymanKY1-1111Cayman Islands 香港主要營業地點及總部 PRINCIPAL PLACE OF BUSINESS AND HEADOFFICE IN HONG KONG 香港畢打街1–3號中建大廈1535室 Suite 1535, Central Building1–3 Pedder StreetHong Kong 股份過戶登記總處 PRINCIPAL SHARE REGISTRAR Conyers Trust Company (Cayman) LimitedCricket Square, Hutchins DriveP.O. Box 2681Grand Cayman, KY1-1111Cayman Islands Conyers Trust Company (Cayman) LimitedCricket Square, Hutchins DriveP.O. Box 2681Grand Cayman, KY1-1111Cayman Islands Corporate Information公司資料 HONG KONG BRANCH SHARE REGISTRAR 香港股份過戶登記分處 Computershare Hong Kong Investor Services LimitedShops 1712–1716, 17th FloorHopewell Centre183 Queen’s Road EastWanchaiHong Kong 香港中央證券登記有限公司香港灣仔皇后大道東183號合和中心17樓1712–1716號舖 PRINCIPAL BANKERS 主要往來銀行 The Bank of East Asia, LimitedBank of China (Hong Kong) LimitedBank of Communications Co., Ltd.Industrial and Commercial Bank of China LimitedThe Hongkong and Shanghai Banking Corporation Limited 東亞銀行有限公司中國銀行（香港）有限公司交通銀行股份有限公司中國工商銀行股份有限公司香港上海滙豐銀行有限公司 LEGAL ADVISOR ON HONG KONG LAWS 香港法律顧問 方達律師事務所香港中環康樂廣場8號交易廣場1期26樓 Fangda Partners26th Floor, One Exchange Square8 Connaught PlaceCentral, Hong Kong COMPANY WEBSITEwww.cmermedical.com 公司網站www.cmermedical.com 股份代號03309 STOCK CODE03309 Management Discussion and Analysis管理層討論及分析 業務回顧 BUSINESS REVIEWOverview 概覽 As a result of the slight increase of revenue and theeffectiveness of our strategies to optimise our servicenetwork and enhance operating efficiency, which includedthe closure of non-performing operations and adoption ofcost-saving measure, the Group’s profitability improved forthe six months ended 30 June 2025 (“1H2025”) as comparedwith the same period in 2024 (“1H2024”). Excluding the lossfrom the Mainland China other business segment (primarilycomprising our C+ Health (Shenzhen) Hospital ( 深 圳 希 華 愛康 健 醫 院 ) which is providing dental, ophthalmic, medicalimaging and other medical services and is still at its initialoperating stage), the profit for the period attributable toequity holders of the Company of the remaining threesegments (the“adjusted profit for the period attributableto equity holders of the Company”) increased by 74.5% toHK$69.6 million in 1H2025 as compared to HK$39.9 millionfor 1H2024. Profit for the period attributable to equityholders of the Company increased by 62.4% to HK$49.9million in 1H2025 as compared to HK$30.8 million for1H2024. In addition, our segment result in Mainland Chinaophthalmic business turned into breakeven in 1H2025 fromthe segment loss of HK$23.0 million in 1H2024. 由於收益略有增長，以及我們優化服務網絡及提高營運效率的策略卓有成效（其中包括關閉表現欠佳的業務及採取節約成本的措施），與2024年同期（「2024年上半年」）比較，本集團於截至2025年6月30日止六個月（「2025年上半年」）的盈利能力有所改善。撇除中國內地其他業務分部（主要包括包含牙科、眼科、醫學影像科及其他醫療服務且正處於初期營運階段的深圳希華愛康健醫院）的虧損，2025年上半年其餘三個分部的本公司權益持